Longevity Health (XAGE) stock rocketed higher on Tuesday after the plasma-based bioactive material developer announced a deal with True Health, operator of the THPlasma and a large player in the plasma collection industry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Under the terms of the deal, the two companies will combine in an all-stock transaction. This deal values THPlasma at $59 million, plus an additional $20 million earnout linked to financial results. The Boards of Directors managing both companies have given their unanimous support to the merger, which is set to close in the fourth quarter of 2025. The surviving company will continue to trade under the XAGE stock ticker.
As part of this merger agreement, Longevity Health and 20/20 BioLabs have announced the mutual termination of their prior agreement.
Longevity Health Stock Movement Today
Longevity Health stock was up 133.65% in pre-market trading on Tuesday, following a 1.31% drop yesterday. Investors will also note that the shares were down 68.4% year-to-date and 94.2% over the past 12 months. Today’s rally came with heavy trading, as some 34 million shares changed hands, compared to a three-month daily average of about 73,000 units.
